Last reviewed · How we verify
Ranibizumab and laser
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue.
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue. Used for Proliferative diabetic retinopathy, Retinal vein occlusion with neovascularization.
At a glance
| Generic name | Ranibizumab and laser |
|---|---|
| Sponsor | Fukushima Medical University |
| Drug class | VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab is a monoclonal antibody fragment that inhibits VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. The combination with laser therapy provides dual mechanisms: anti-VEGF suppression of abnormal vessel formation and growth, plus direct thermal ablation of ischemic or neovascular retinal areas. This combination approach targets both the molecular driver and the structural pathology of proliferative retinal disease.
Approved indications
- Proliferative diabetic retinopathy
- Retinal vein occlusion with neovascularization
Common side effects
- Endophthalmitis
- Retinal detachment
- Cataract progression
- Intraocular pressure elevation
- Floaters
Key clinical trials
- Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns (PHASE3)
- Combination of Ranibizumab and Targeted Laser Photocoagulation (PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging (PHASE1, PHASE2)
- Rainbow Extension Study (PHASE3)
- Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.
- Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity (PHASE3)
- Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranibizumab and laser CI brief — competitive landscape report
- Ranibizumab and laser updates RSS · CI watch RSS
- Fukushima Medical University portfolio CI